Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Evoke Pharma Inc EVOK

Healthcare
Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. The Company operates through the development and commercialization of pharmaceutical products. It is developing its product, Gimoti (metoclopramide) nasal spray, the first and only nasally administered... see more

Recent & Breaking News (NDAQ:EVOK)

Evoke Pharma Reports First Quarter 2022 Financial Results

GlobeNewswire May 10, 2022

Evoke Pharma to Report First Quarter 2022 Financial Results on May 10, 2022

GlobeNewswire May 3, 2022

Evoke Pharma Granted FDA Market Exclusivity for GIMOTI®

GlobeNewswire April 26, 2022

Evoke Pharma Announces Approval of GIMOTI® to the Texas Medicaid Preferred Drug List

GlobeNewswire April 19, 2022

Evoke Pharma Announces Key Opinion Leader Fireside Chat to Discuss Gastroparesis Treatment Landscape

GlobeNewswire March 10, 2022

Evoke Pharma Reports Fourth Quarter and Full Year 2021 Financial Results

GlobeNewswire March 8, 2022

Evoke Pharma to Report Fourth Quarter and Full Year 2021 Financial Results on March 8, 2022

GlobeNewswire March 1, 2022

Evoke Pharma and EVERSANA Announce Acceptance of Abstract for Poster of Distinction Presentation at Digestive Disease Week (DDW) May 2022

GlobeNewswire February 24, 2022

GIMOTI® Commercialization Update

GlobeNewswire February 17, 2022

Evoke Pharma and EVERSANA Extend Commercialization Partnership to Further Support GIMOTI

GlobeNewswire February 2, 2022

Evoke Pharma to Participate in the H.C. Wainwright BIOCONNECT Virtual Conference

GlobeNewswire January 4, 2022

Evoke Pharma Reports Third Quarter 2021 Financial Results

GlobeNewswire November 10, 2021

Evoke Pharma to Report Third Quarter 2021 Financial Results on November 10, 2021

GlobeNewswire November 3, 2021

Evoke Pharma and EVERSANA Announce Positive Findings from GIMOTI® Market Research Study

GlobeNewswire October 20, 2021

Evoke Pharma's Commercial Partner EVERSANA, Receives PM360's Trailblazer Initiative Award for Innovation in Healthcare Marketing for GIMOTI

GlobeNewswire September 29, 2021

Evoke Pharma to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

GlobeNewswire September 1, 2021

Evoke Pharma Reports Second Quarter 2021 Financial Results

GlobeNewswire August 12, 2021

Evoke Pharma to Report Second Quarter 2021 Financial Results on August 12, 2021

GlobeNewswire August 5, 2021

Evoke Pharma and EVERSANA Announce Support of The International Foundation for Gastrointestinal Disorders' (IFFGD) August Gastroparesis Awareness Month

GlobeNewswire August 2, 2021

Evoke Pharma Launches Gimoti® Patient and Physician Experience Program

GlobeNewswire July 14, 2021